Breaking
Anthropic Fights Trump Administration Over AI Model Export ControlsTrump and Iran Reach Initial Agreement to End War, Reopen Strait of HormuzElection Conspiracy Theorist Wins Nevada GOP Secretary of State PrimaryIsar Aerospace Faces New Delays in Spectrum Rocket Test FlightsFormer Louisville Officer Charged with Manslaughter in Fatal ShootingGoogle CEO Sundar Pichai Faces Student Protest at Stanford CommencementFormer ICE Acting Director Todd Lyons Hired by Defense ContractorGeorgia GOP Primary Runoff Exposes Party DivisionsRecall Issued for Alfredo Sauce Due to Potential Salmonella ContaminationUN Security Council Urges Taliban to Reverse Women's Crackdown, Combat MilitantsAnthropic Fights Trump Administration Over AI Model Export ControlsTrump and Iran Reach Initial Agreement to End War, Reopen Strait of HormuzElection Conspiracy Theorist Wins Nevada GOP Secretary of State PrimaryIsar Aerospace Faces New Delays in Spectrum Rocket Test FlightsFormer Louisville Officer Charged with Manslaughter in Fatal ShootingGoogle CEO Sundar Pichai Faces Student Protest at Stanford CommencementFormer ICE Acting Director Todd Lyons Hired by Defense ContractorGeorgia GOP Primary Runoff Exposes Party DivisionsRecall Issued for Alfredo Sauce Due to Potential Salmonella ContaminationUN Security Council Urges Taliban to Reverse Women's Crackdown, Combat Militants
Newsgather

gene editing

Steady2 stories2 sourcesLast updated: 4/28/2026
Related Topicsthalassaemiagene therapyCS-101base editingShanghaiTech Universitybeta-thalassaemiahaemoglobintBE

Latest Stories

Chinese Scientists Develop Gene Therapy CS-101 Curing Five Beta-Thalassaemia Patients
Developing
Science·4/28/2026AI summary

Chinese Scientists Develop Gene Therapy CS-101 Curing Five Beta-Thalassaemia Patients

Scientists at ShanghaiTech University have developed CS-101, a base-editing gene therapy that successfully cured five Chinese patients with beta-thalassaemia. The treatment restored haematopoietic function, raising total haemoglobin and fetal haemoglobin levels, freeing patients from lifelong blood transfusions. China has 30 million thalassaemia gene carriers while the global total reaches 350 million.

S
SCMP Economy
Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks
Developing
Science·4/27/2026AI summary

Intellia's CRISPR Treatment Shows 87% Reduction in Hereditary Angioedema Attacks

Intellia Therapeutics' CRISPR-based treatment for hereditary angioedema met its goals in a Phase 3 trial, reducing attacks by 87% compared with placebo. The one-time infusion therapy edits genes directly in the liver and achieved 62% of patients being attack-free six months after treatment. The company has started a rolling FDA application and plans to launch in the first half of next year if approved.

C
CNBC